Log in Free sign up

Chromadex (CDXC) News and press releases

News

From Benzinga Pro

Mosaic Tumbles Around 10%, Here's 71 Biggest Movers From Yesterday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ: BHAT) shares jumped 263% to $2.73 on Thursday. Blue Hat Interactive terminated its previously proposed shelf takedown offering.

44 Stocks Moving In Thursday's Mid-Day Session: F-star Therapeutics, Revlon And More

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ: BHAT) rose 83.8% to $1.3824. Blue Hat Interactive terminated its previously proposed shelf takedown offering.

ChromaDex Signs Distribution Agreement With Sinopharm Xingsha Accelerate Cross-Border Sales Of Tru Niagen Into Mainland China

Under the distribution agreement, all cross-border operations in the region will be transitioned to Sinopharm, with Sinopharm investments to amplify Tru Niagen® brand awareness, as a first step in

4 Analysts Have This to Say About ChromaDex

Analyst Ratings

ChromaDex (NASDAQ:CDXC) has observed the following analyst ratings within the last quarter:

HC Wainwright & Co. Maintains Buy on ChromaDex, Lowers Price Target to $7

News, Price Target, Analyst Ratings

HC Wainwright & Co. analyst Raghuram Selvaraju maintains ChromaDex (NASDAQ:CDXC) with a Buy and lowers the price target from $8 to $7.

ChromaDex Partners With Juvenis For Cross-Border Sales Of Tru Niagen Into South Korea

ChromaDex Corp. (NASDAQ:CDXC) today announced a partnership with Juvenis to conduct cross-border sales of Tru Niagen® in South Korea. Juvenis is a Korean healthcare marketing company with a focus on the cosmetic and

ChromaDex Establishes Joint Venture For Tru Niagen Distribution In China

News, Penny Stocks, Health Care, Contracts, Movers, Trading Ideas, General

12 Health Care Stocks Moving In Thursday's After-Market Session

Gainers Radius Health (NASDAQ:RDUS) stock moved upwards by 18.8% to $6.94 during Thursday's after-market session. The company's market cap stands at $330.1 million.

ChromaDex Announces Agreement To Launch Commercial Joint Venture In Mainland China

News, Contracts

ChromaDex Corp. (NASDAQ:CDXC) ("the Company") a global bioscience company dedicated to healthy aging, today announced it has entered into an agreement (the "JV Agreement") to establish a joint venture

Where ChromaDex Stands With Analysts

Analyst Ratings

Within the last quarter, ChromaDex (NASDAQ:CDXC) has observed the following analyst ratings:

Stocks That Hit 52-Week Lows On Friday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Friday, 153 companies set new 52-week lows.

B. Riley Securities Maintains Buy on ChromaDex, Lowers Price Target to $6

News, Price Target, Analyst Ratings

B. Riley Securities analyst Jeff Van Sinderen maintains ChromaDex (NASDAQ:CDXC) with a Buy and lowers the price target from $8 to $6.

Recap: ChromaDex Q1 Earnings

ChromaDex (NASDAQ:CDXC) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings ChromaDex missed estimated earnings by 22.22%, reporting an EPS of $-0.11 versus an estimate of $-0.09.

ChromaDex Q1 EPS $(0.11) Misses $(0.09) Estimate, Sales $17.30M Beat $17.23M Estimate

ChromaDex (NASDAQ:CDXC) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.09) by 22.22 percent. This is a 8.33 percent increase over losses of $(0.12) per share from the

Earnings Scheduled For May 12, 2022

Earnings, News, Pre-Market Outlook, Markets

Companies Reporting Before The Bell • Chicago Atlantic Real (NASDAQ:REFI) is projected to report earnings for its first quarter.

Stocks That Hit 52-Week Lows On Friday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Friday, 1043 companies hit new 52-week lows.

Stocks That Hit 52-Week Lows On Thursday

News, Options, Intraday Update, Markets

During Thursday, 849 stocks hit new 52-week lows.

Stocks That Hit 52-Week Lows On Monday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Monday, 721 companies achieved new lows for the year.

HC Wainwright & Co. Maintains Buy on ChromaDex, Lowers Price Target to $8

News, Price Target, Analyst Ratings

HC Wainwright & Co. analyst Raghuram Selvaraju maintains ChromaDex (NASDAQ:CDXC) with a Buy and lowers the price target from $12 to $8.

ChromaDex Launches Tru Niagen Immune

Tru Niagen® Immune is the first-ever immune health supplement with a targeted NAD+ boost for the optimal maintenance and function of aging cells ChromaDex Corp. (NASDAQ:CDXC) today announced the company's

Press releases

From Benzinga Pro

ChromaDex to Present at American Society for Nutrition (ASN), International Society of Sports Nutrition (ISSN), and Federation of American Societies for Experimental Biology (FASEB)

As a pioneer of nicotinamide adenine dinucleotide (NAD+) and healthy aging research, ChromaDex aims to raise awareness amongst industry leaders ChromaDex Corp. (NASDAQ:CDXC) today announced that members of its team, a

Thinking about buying stock in Nio, Redbox Entertainment, Agora, Chromadex, or Beyondspring?

Opinion, Press Releases

NEW YORK, June 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NIO, RDBX, API, CDXC, and BYSI.

ChromaDex Signs Sinopharm Xingsha Agreement to Accelerate Cross-Border Sales of Tru Niagen® into Mainland China

Under the distribution agreement, all cross-border operations in the region will be transitioned to Sinopharm, with Sinopharm investments to amplify Tru Niagen® brand awareness, as a first step in ChromaDex's

ChromaDex to Present at the Oppenheimer's 22nd Annual Consumer Growth and E-Commerce Conference

ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting at Oppenheimer's 22nd Annual Consumer Growth and E-Commerce

ChromaDex Partners with Juvenis for Cross-Border Sales of Tru Niagen® into South Korea

Tru Niagen® enters the international market with digital cross-border launch strategy ChromaDex Corp. (NASDAQ:CDXC) today announced a partnership with Juvenis to conduct cross-border sales of Tru Niagen® in

ChromaDex to Present at the LD Micro Invitational

ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting virtually at the 12th annual Invitational. This three-day investor

ChromaDex Announces Agreement to Launch Commercial Joint Venture in Mainland China

The signed agreement establishes beachhead to broadly market and distribute Tru Niagen® to Mainland China's aging population ChromaDex Corp. (NASDAQ:CDXC) ("the Company") a global bioscience company dedicated to

ChromaDex Wins International 2022 European NutraIngredients Award for Developing the Science Behind Niagen®

The ChromaDex External Research Program (CERPTM) was honored in the "Nutrition Research Project" category for pioneering research behind Niagen® ChromaDex Corp. (NASDAQ:CDXC) announced today that NutraIngredients,

ChromaDex Corporation Reports First Quarter 2022 Financial Results

Total net sales of $17.3 million for the three months ended March 31, 2022, up 18% from the prior year, with $14.9 million from Tru Niagen® and gross margin of 61.0% for the quarter. ChromaDex Corp. (NASDAQ:CDXC)

ChromaDex to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs. May 12, 2022 at 4:30 p.m. ET to discuss its financial results for the first quarter, which ended March 31, 2022. The financial

ChromaDex Appoints Ann Cohen and Kristin Patrick to its Board of Directors

ChromaDex Corp. (NASDAQ:CDXC) today announced that it has appointed two new members to its Board of Directors: Kristin Patrick, Executive Vice President and Chief Marketing Officer of Claire's Inc., and Ann Cohen,

ChromaDex External Research Program (CERP™) Celebrates Over 250 Research Agreements With 235+ Researchers Around the World

ChromaDex's research and development program reaches over 250 material transfer agreements (MTAs) on Niagen® and other ingredients, marking a milestone in NAD+ research ChromaDex Corp. (NASDAQ:CDXC) today

ChromaDex Launches Tru Niagen® Immune, Further Expanding Innovative Product Portfolio

Tru Niagen® Immune is the first-ever immune health supplement with a targeted NAD+ boost for the optimal maintenance and function of aging cells ChromaDex Corp. (NASDAQ:CDXC) today announced the company's latest